Cytomegalovirus Reactivation in Ovarian Cancer

Abstract

There is a pressing need to identify new biomarkers that can be used to tailor treatment and improve outcomes in ovarian cancer. This project will test the hypothesis that a common herpes virus, cytomegalovirus (CMV), re-emerges from latency during ovarian cancer and negatively impacts ovarian cancer treatment. Among 50 women diagnosed with ovarian cancer and receiving chemotherapy we will measure: CMV in blood at the time of diagnosis, CMV in tumor, CMV in blood during chemotherapy treatment, inflammation, and severity of symptoms during treatment. Our objective is to determine whether this very common virus re-emerges during chemotherapy and negatively impacts the patient during ovarian cancer treatment.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2020
Accession Number
AD1114608

Entities

People

  • Heather H. Nelson
  • Melissa Geller
  • Rachel Vogel

Organizations

  • University of Minnesota

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Acquisition
  • Biomedical Research
  • Blood
  • Breast Cancer
  • Cancer
  • Cancer Screening
  • Cells
  • Cervical Cancers
  • Chemotherapy
  • Data Analysis
  • Department Of Defense
  • Drug Therapy
  • Education
  • Environmental Monitoring
  • Health
  • Kinetics
  • Medical Personnel
  • Minnesota
  • Neoplasms
  • Ovarian Cancer
  • Statistical Analysis
  • Stem Cells
  • Therapy
  • Universities
  • Wearable Technology

Readers

  • Molecular Biology and Genetics
  • Toxicology/Environmental Toxicology
  • Virology (or Medical Virology).